BillionToOne, Inc. (BLLN)
| Market Cap | 4.46B |
| Revenue (ttm) | 354.54M +100.3% |
| Net Income | 24.88M |
| EPS | 0.78 |
| Shares Out | 46.00M |
| PE Ratio | 124.55 |
| Forward PE | 101.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 246,942 |
| Open | 96.17 |
| Previous Close | 94.43 |
| Day's Range | 95.32 - 101.74 |
| 52-Week Range | 61.96 - 138.70 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 117.71 (+21.45%) |
| Earnings Date | May 6, 2026 |
About BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for BLLN stock is "Buy." The 12-month stock price target is $117.71, which is an increase of 21.45% from the latest price.
News
BillionToOne Transcript: 46th Annual William Blair Growth Stock Conference
Patented single molecule diagnostics technology has driven exponential revenue growth, high gross margins, and GAAP profitability. Category-defining products in prenatal and oncology have changed medical guidelines and treatment paradigms, with ongoing innovation and ambitious growth targets.
BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are ac...
BillionToOne price target raised to $120 from $100 at Guggenheim
Guggenheim raised the firm’s price target on BillionToOne (BLLN) to $120 from $100 and keeps a Buy rating on the shares after having hosted management for a series of investor…
BillionToOne price target raised to $125 from $120 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on BillionToOne (BLLN) to $125 from $120 and keeps an Overweight rating on the shares.
BillionToOne price target lowered to $130 from $140 at BTIG
BTIG lowered the firm’s price target on BillionToOne (BLLN) to $130 from $140 and keeps a Buy rating on the shares.
BillionToOne sees FY26 revenue $450M-$465M, consensus $437.6M
Expects to operate the business such that it will continue to generate profitability approaching current levels, even with significant continued investments.
BillionToOne reports Q1 EPS 34c, consensus 4c
Reports Q1 revenue $108.39M, consensus $96.89M. “Our first quarter performance underscores the continued momentum we are building through our differentiated technology platform, category-defining prod...
BillionToOne Earnings Call Transcript: Q1 2026
Q1 2026 saw 84% revenue growth, strong profitability, and major product launches, including UNITY Confirm. Gross margins reached 73%, and 2026 revenue guidance was raised to $450–$465 million, driven by higher ASPs and expanded payer coverage.
BillionToOne Slides: Q1 2026
BillionToOne has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
BillionToOne Earnings release: Q1 2026
BillionToOne released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
BillionToOne Quarterly report: Q1 2026
BillionToOne has published its Q1 2026 quarterly earnings report on May 6, 2026.
BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are ac...
BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics
A breakthrough in prenatal care, Unity Confirm enables non-invasive confirmation for high-risk screening results through the capture of intact circulating fetal cells using BillionToOne's Fetal Cell C...
BillionToOne Proxy statement: Proxy filing
BillionToOne filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
BillionToOne Proxy statement: Proxy filing
BillionToOne filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology
Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategy MENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne , Inc. (Nasdaq: BLLN), a nex...
BillionToOne price target lowered to $100 from $120 at Guggenheim
Guggenheim lowered the firm’s price target on BillionToOne (BLLN) to $100 from $120 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies…
BillionToOne price target lowered to $140 from $160 at BTIG
BTIG lowered the firm’s price target on BillionToOne (BLLN) to $140 from $160 and keeps a Buy rating on the shares. The company hosted a very upbeat Q4 earnings call…
BillionToOne price target lowered to $140 from $160 at BTIG
BTIG lowered the firm’s price target on BillionToOne (BLLN) to $140 from $160 and keeps a Buy rating on the shares. The company hosted a very upbeat Q4 earnings call…
BillionToOne price target lowered to $90 from $110 at Wells Fargo
Wells Fargo analyst Brandon Couillard lowered the firm’s price target on BillionToOne (BLLN) to $90 from $110 to reflect recent peer group multiple compression, while keeping an Equal Weight rating…
BillionToOne reports Q4 EPS 11c, consensus 17c
Reports Q4 revenue $96.05M, consensus $87.2M. “2025 demonstrated how the compounding power of a differentiated technology platform, category-defining products, and disciplined execution can produce an...
BillionToOne raises FY26 revenue view to $430M-$445M from $415M-$430M
Consensus $396.73M. The company said, “BillionToOne (BLLN) now expects full year 2026 total revenue of $430 million to $445 million, representing growth of 41% to 46% compared to full year…
BillionToOne Earnings Call Transcript: Q4 2025
Delivered 100% year-over-year revenue growth in 2025, with Q4 revenue up 113% and gross margin reaching 71.4%. Raised 2026 revenue guidance to $430–$445 million, driven by strong prenatal and oncology growth, new product launches, and expanded payer coverage.
BillionToOne Annual report: Q4 2025
BillionToOne has published its Q4 2025 annual report on March 4, 2026.
BillionToOne Earnings release: Q4 2025
BillionToOne released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.